Loading clinical trials...
Loading clinical trials...
An open-label, Phase II clinical study to evaluate the efficacy and safety of lanreotide autogel 90mg every 4 weeks in the treatment of symptomatic polycystic liver disease, including a dose escalatio...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborators
NCT05478083 · Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney
NCT05215964 · Polycystic Kidney Diseases, Polycystic Liver Disease, and more
NCT01670110 · Somatostatin Analogs, Polycystic Liver Disease, and more
NCT01354405 · Polycystic Liver Disease
UZ Leuven, Gasthuisberg
Leuven, Provincie Vlaams-Brabant
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions